Insufficient scRNA-seq data for expression of PLAAT5 at tissue level.
Tissue | GTEx Coverage  | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| breast | 99% | 1791.81 | 455 / 459 | 76% | 14.13 | 850 / 1118 |
| pancreas | 98% | 693.91 | 322 / 328 | 58% | 2.39 | 104 / 178 |
| brain | 79% | 360.23 | 2099 / 2642 | 75% | 4.05 | 526 / 705 |
| ovary | 77% | 244.63 | 139 / 180 | 33% | 0.82 | 144 / 430 |
| adipose | 100% | 2150.89 | 1198 / 1204 | 0% | 0 | 0 / 0 |
| bladder | 71% | 193.62 | 15 / 21 | 23% | 1.40 | 115 / 504 |
| intestine | 66% | 258.33 | 641 / 966 | 24% | 1.85 | 128 / 527 |
| esophagus | 63% | 304.38 | 910 / 1445 | 26% | 1.68 | 48 / 183 |
| stomach | 55% | 145.19 | 199 / 359 | 26% | 1.64 | 74 / 286 |
| lung | 47% | 156.62 | 270 / 578 | 31% | 2.35 | 361 / 1155 |
| uterus | 54% | 172.19 | 91 / 170 | 23% | 1.36 | 104 / 459 |
| kidney | 34% | 85.61 | 30 / 89 | 42% | 1.64 | 377 / 901 |
| prostate | 35% | 78.13 | 86 / 245 | 30% | 0.53 | 153 / 502 |
| skin | 23% | 51.38 | 408 / 1809 | 27% | 3.26 | 126 / 472 |
| heart | 46% | 118.53 | 394 / 861 | 0% | 0 | 0 / 0 |
| adrenal gland | 35% | 76.33 | 91 / 258 | 10% | 0.42 | 24 / 230 |
| blood vessel | 28% | 107.57 | 371 / 1335 | 0% | 0 | 0 / 0 |
| thymus | 6% | 15.38 | 39 / 653 | 4% | 0.06 | 23 / 605 |
| eye | 0% | 0 | 0 / 0 | 5% | 0.12 | 4 / 80 |
| tonsil | 0% | 0 | 0 / 0 | 4% | 0.08 | 2 / 45 |
| liver | 0% | 0.58 | 1 / 226 | 3% | 0.17 | 11 / 406 |
| peripheral blood | 2% | 4.60 | 20 / 929 | 0% | 0 | 0 / 0 |
| muscle | 1% | 3.10 | 10 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spleen | 0% | 0 | 0 / 241 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0070292 | Biological process | N-acylphosphatidylethanolamine metabolic process |
| GO_0005829 | Cellular component | cytosol |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0004623 | Molecular function | phospholipase A2 activity |
| GO_0016410 | Molecular function | N-acyltransferase activity |
| GO_0008970 | Molecular function | phospholipase A1 activity |
| GO_0052739 | Molecular function | phosphatidylserine 1-acylhydrolase activity |
| GO_0052740 | Molecular function | 1-acyl-2-lysophosphatidylserine acylhydrolase activity |
| Gene name | PLAAT5 |
| Protein name | Phospholipase A and acyltransferase 5 HRASLS5 protein Phospholipase A and acyltransferase 5 (Ca(2+)-independent N-acyltransferase) (iNAT) (EC 2.3.1.-, EC 3.1.1.32, EC 3.1.1.4) (H-rev107-like protein 5) (HRAS-like suppressor 5) (HRSL5) |
| Synonyms | HRASLS5 HRLP5 |
| Description | FUNCTION: Exhibits both phospholipase A1/2 and acyltransferase activities . Shows phospholipase A1 (PLA1) and A2 (PLA2) activity, catalyzing the calcium-independent release of fatty acids from the sn-1 or sn-2 position of glycerophospholipids . Shows N-acyltransferase activity, catalyzing the calcium-independent transfer of a fatty acyl group at the sn-1 position of phosphatidylcholine (PC) and other glycerophospholipids to the primary amine of phosphatidylethanolamine (PE), forming N-acylphosphatidylethanolamine (NAPE), which serves as precursor for N-acylethanolamines (NAEs) . . |
| Accessions | ENST00000539221.5 [Q96KN8-2] Q96KN8 H0YGT7 ENST00000540857.6 [Q96KN8-3] ENST00000538712.1 ENST00000301790.4 [Q96KN8-1] Q8NE88 ENST00000536887.5 F5H4Q3 H7BYL7 ENST00000394615.2 |
